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Vascular calcification predicts atherosclerotic plaque rupture and cardiovascular events. Retrospective studies of women taking bisphosphonates (BiPs), a proposed therapy for vascular calcification, showed
that BiPs paradoxically increased morbidity in patients with prior acute
cardiovascular events but decreased mortality in event-free patients.
Calcifying extracellular vesicles (EVs), released by cells within atherosclerotic plaques, aggregate and nucleate calcification. We hypothesized that BiPs block EV aggregation and modify existing mineral
growth, potentially altering microcalcification morphology and the risk
of plaque rupture. Three-dimensional (3D) collagen hydrogels incubated with calcifying EVs were used to mimic fibrous cap calcification
in vitro, while an ApoE−/− mouse was used as a model of atherosclerosis in vivo. EV aggregation and formation of stress-inducing microcalcifications was imaged via scanning electron microscopy (SEM) and
atomic force microscopy (AFM). In both models, BiP (ibandronate)
treatment resulted in time-dependent changes in microcalcification
size and mineral morphology, dependent on whether BiP treatment
was initiated before or after the expected onset of microcalcification
formation. Following BiP treatment at any time, microcalcifications
formed in vitro were predicted to have an associated threefold decrease in fibrous cap tensile stress compared to untreated controls,
estimated using finite element analysis (FEA). These findings support
our hypothesis that BiPs alter EV-driven calcification. The study also
confirmed that our 3D hydrogel is a viable platform to study EVmediated mineral nucleation and evaluate potential therapies for
cardiovascular calcification.
atherosclerosis

Histologic studies have revealed the presence of cell-derived
vesicles within calcifying atherosclerotic lesions (13–16). The
inflammatory environment of the atherosclerotic lesion can induce vascular smooth muscle cells (vSMCs) to take on an
osteochondrogenic phenotype and release calcifying extracellular vesicles (EVs) (17–19). Macrophages have also been shown
to release procalcifying vesicles (20, 21). Thus, just as bone
formation is hypothesized to be an active, cell-driven process (22,
23), mediated by calcifying matrix vesicles, atheroma-associated
calcification may similarly be initiated by the production and
aggregation of calcifying EVs (11, 20, 24–28).
Significance
The most common cause of heart attacks or strokes is the
rupture of thin fibrous caps that cover vulnerable plaques
within blood vessels. Small mineral deposits, called microcalcifications, increase local tissue stress and thereby increase
the risk of cap rupture. We report here the use of a threedimensional collagen hydrogel model of fibrous cap calcification and a complementary mouse model of plaque formation
to determine whether bisphosphonate (BiP) therapy, commonly used to treat bone loss, alters microcalcification formation. The results showed that BiP treatment resulted in timedependent changes in microcalcification size and mineral
morphology, dependent on whether BiP treatment was initiated before or after the expected onset of microcalcification
formation.
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therosclerotic plaque rupture is the leading cause of myocardial infarction and stroke (1, 2). Studies assessing the
correlation between calcium scores and cardiovascular events have
demonstrated a predictive power that is superior to and independent from that of lipid scores (3, 4). Additionally, clinical
imaging studies have revealed that the risk of plaque rupture is
further heightened by the presence of small, “spotty” calcifications, or microcalcifications (5, 6), and cardiovascular risk is inversely correlated with the size of calcific deposits, quantified as a
calcium density score (7). Indeed, computational modeling has
demonstrated that, while large calcifications can reinforce the fibrous cap (8), microcalcifications (typically 5 to 15 μm in diameter) uniquely mediate an increase in mechanical stress of the
relatively soft, collagen-rich fibrous cap (9–12).
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One proposed strategy for halting pathologic calcification has
been the use of bisphosphonates (BiPs). BiPs are analogs of pyrophosphate (29), a naturally occurring compound derived in vivo
from adenosine triphosphate (ATP) (30). Pyrophosphate binds to
calcium phosphate and inhibits calcification via physicochemical
mechanisms, namely, by blocking calcium and phosphate ions from
forming crystals, preventing crystal aggregation, and preventing
mineral transformation from amorphous calcium phosphate to
hydroxyapatite (29). BiPs were identified as pyrophosphate analogs
that, unlike pyrophosphate itself, resist enzymatic hydrolysis. A
second, distinct property of BiPs is the ability to inhibit bone resorption via biological activity directed against osteoclasts following
osteoclast endocytosis of the BiP molecule adsorbed to the surface
of bone (29, 31). First-generation, or nonnitrogen-containing BiPs,
are incorporated into nonhydrolyzable ATP analogs, and induce
osteoclast apoptosis by limiting ATP-dependent enzymes. In contrast, nitrogen-containing BiPs inhibit farnesyl pyrophosphate synthetase and thereby induce osteoclast apoptosis (31).
In vivo animal investigations have been performed to explore the
potential for BiPs to inhibit cardiovascular calcification. Studies of
first-generation BiPs revealed that the doses required to inhibit
cardiovascular calcification also critically compromised normal
bone mineralization (29, 32). However, newer, nitrogen-containing
BiPs effectively arrested cardiovascular calcification in animal
models at doses that did not compromise bone formation (32).
Further, while it has been proposed that BiP treatment modifies
cardiovascular calcification via its impact on bone-regulated circulating calcium and phosphate levels, a study in uremic rats demonstrated that BiP treatment inhibited medial aortic calcification
with no significant change in plasma calcium and phosphate levels
(33). The same study demonstrated that BiP treatment inhibited
calcification of explanted rat aortas, indicating that BiPs can act
directly on vascular tissue, independent of bone metabolism (33).
Retrospective clinical data examining the effect of BiP therapy
on cardiovascular calcification has demonstrated conflicting findings and intriguing paradoxes. In women with chronic kidney
disease, BiP therapy decreased the mortality rate for patients
without a prior history of cardiovascular disease (34), but for those
patients with a history of prior cardiovascular events, BiP therapy
was associated with an increased mortality rate (35). In another
study, BiP therapy correlated with a lower rate of cardiovascular
calcification in older patients (>65 y), but a greater rate in younger
patients (<65 y) (36). These clinical findings motivated our study,
in which we sought to further understand how BiP therapy impacts
cardiovascular outcomes. Given that cardiovascular calcification,
and especially the presence of microcalcification, is a strong and
independent risk factor for adverse cardiac events, and BiPs are
prescribed to modulate pathologies of mineralization, we hypothesize that BiPs modulate cardiovascular outcomes by altering
the dynamics of cardiovascular calcification.
EVs are smaller than the resolution limits of traditional microscopy techniques, hindering studies into the mechanisms of
calcification nucleation and growth. We previously developed an
in vitro collagen hydrogel platform that allowed the visualization
of calcific mineral development mediated by EVs isolated from
vSMCs (24). Using superresolution microscopy, confocal, and
electron microscopy techniques, we showed that calcification
requires the accumulation of EVs that aggregate and merge to
build mineral. Collagen serves as a scaffold that promotes associations between EVs that spread into interfibrillar spaces. The
resultant mineral that forms within the collagen hydrogel appears spectroscopically similar to microcalcifications in human
tissues and allows the study of these structures on the time scale
of 1 wk. In this study, we utilized this three-dimensional (3D)
acellular platform to examine the direct effect of ibandronate, a
nitrogen-containing BiP, on the EV-directed nucleation and
growth of microcalcifications, a process that cannot be isolated
from cellular and tissue-level mechanisms in a more complex,
2 of 10 | PNAS
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in vivo system. In parallel, we utilized a mouse model of atherosclerosis to assess the effect of ibandronate therapy on plaqueassociated calcification, comparing mineral morphologies between the in vitro and in vivo samples. We hypothesize that BiPs
block EV aggregation and modify existing mineral growth, potentially altering microcalcification morphology and the risk of
plaque rupture. Understanding the EV-specific action of BiPs is
imperative both to develop anticalcific therapeutics targeting EV
mineralization and to understand one potential mechanism driving the cardiovascular impact of BiPs used in clinical settings.
Results
The 3D collagen hydrogels were incubated with calcifying EVs in
osteogenic medium for 8 d (Fig. 1). The characterization of calcifying EVs is presented in the supplemental information (SI
Appendix, Figs. S1–S3). Scanning electron microscopy (SEM)
revealed the aggregation of EVs along and between collagen fibrils
(Fig. 2 A, B, and D). The EV aggregates formed in vitro resembled
aggregates of dense, spherical particles visualized within a calcified
region of a human atherosclerotic plaque, imaged using densitydependent color SEM (DDC-SEM) (37) (Fig. 2C). Using transmission electron microscopy (TEM), similar, rough appearing
vesicular structures were identified in sections of EV-incubated
hydrogels and in human atherosclerotic tissue (Fig. 2 E and F,
respectively). Confocal microscopy of collagen hydrogels stained
with a fluorescent calcium tracer confirmed that incubation with
calcifying EVs led to the formation of structures composed of
calcium phosphate mineral, i.e., microcalcifications (Fig. 3A).
Energy dispersive spectroscopy (EDS), a technique used to analyze elemental composition concurrent with SEM, demonstrated
that EV aggregates formed in our 3D platform contained phosphorous and calcium (Fig. 3B). EDS mapping of EV aggregates
(Fig. 3C) further visualized the phosphorous (Fig. 3D) and calcium
(Fig. 3E) content of these structures. Additionally, multiscale finite
element analysis (FEA) predicted a 350% increase in tissue stress
(stress concentration factor [SCF]) that would be associated with a
representative microcalcification formed in our in vitro 3D platform (SI Appendix, Fig. S4).
To investigate the effect of BiP treatment on the formation
and growth of EV-nucleated microcalcifications, a single dose of
the BiP ibandronate was added simultaneously with calcifying
EVs to the 3D collagen platform on day 0 of incubation. After
8 d of incubation, SEM images demonstrated that, compared to
untreated samples (Fig. 4 A and C), BiP treatment on day 0 reduced the maximum size of microcalcifications formed in the 3D
system (Fig. 4 B and D). A custom image analysis algorithm was
used to analyze a representative sample of high-powered fields
from each group and revealed a statistically significant decrease
in maximum microcalcification size in BiP-treated samples
(Fig. 4E). EDS analysis of a representative sample for each
group further indicated that BiP treatment altered the elemental
composition of microcalcifications, with a significant decrease in
both calcium and phosphorous (Fig. 4F). There was no difference in tissue non-specific alkaline phosphatase (ALP) activity

Fig. 1. Schematic of assembly and use of 3D collagen platform.
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Fig. 2. The 3D collagen-EV platform recapitulated microcalcifications seen
in human atheroma. (A) SEM image of a microcalcification formed in the 3D
collagen platform after 8 d of incubation with calcifying EVs. (B) Higher
magnification view of yellow-outlined region in B. (C) DDC-SEM image of
calcified atherosclerotic plaque from a human carotid endarterectomy
sample. (D) Higher magnification SEM image of EVs aggregating in the 3D
collagen platform. (E) TEM image of a microcalcification formed in the 3D
collagen platform. (F) TEM image of calcified atherosclerotic plaque from
human tissue sample.

between BiP-treated and untreated EVs following up to 4 h of
incubation (SI Appendix, Fig. S5).
Next, we examined the time-dependent effect of BiP treatment on in vitro microcalcification formation (Fig. 5A). Each
sample received a single dose of BiP, but the time at which the
BiP was added varied. Quantified using a fluorescent-based assay, the amount of calcific mineral detected on day 8 significantly
varied across treatment groups (Fig. 5B, P = 0.0025, via one-way
repeated measures ANOVA). Multiple comparisons testing
revealed a significant difference between the untreated control
and samples treated on day 6 (adjusted P = 0.027), but no difference between the control and samples treated with singledose BiP on days 0, 2, or 4 (Fig. 5B). Notably, a control experiment demonstrated that the degree of calcification observed was
significantly higher for all treatment groups if EVs were incubated in osteogenic medium, as compared to normal medium (SI
Appendix, Fig. S6).
Fourier-transform infrared spectroscopy (FTIR) analysis of all
treatment groups revealed prominent peaks in the 900 to
1,200 cm−1 region, associated with the stretching modes of the
P-O bond in phosphate (38, 39) (Fig. 5C). In the control group,
there was a predominant peak at 1,027 cm−1, with a prominent
shoulder at 1,100 cm−1 and a small shoulder at 960 cm−1, consistent with the known spectral features of hydroxyapatite
(38–44). With BiP treatment, the shoulders at 1,100 cm−1 and
960 cm−1 generally became less prominent, and the predominant
P-O peak decreases in frequency to around 1,021 cm−1 for the
samples treated on day 2 and day 6, and 1,017 cm−1 for the
sample treated on day 4 (Fig. 5C). Given that it has been previously shown that spectral features sharpen with mineral maturity and crystallinity (39, 42, 43), it is possible that BiP
treatment resulted in the formation of a less mature mineral.
Additionally, the predominant P-O peak decreased in frequency
from 1,027 cm−1 to around 1,021 cm−1 in the day 2 and day 6
samples, and 1,017 cm−1 in the day 4 sample. It has been suggested that a decrease in the frequency of this peak is seen in less
crystalline apatite (39). It has also been shown that the ratio of
1,030 cm−1 to 1,020 cm−1 peak intensities are associated with
mineral crystallinity, and thereby, maturity (42, 44). Thus, it is
possible that the decreased frequency of this peak occurred due
to the presence of a less crystalline and less mature mineral in
the BiP-treated samples. The FTIR spectra did not demonstrate
any direct evidence of BiP incorporation into the mineral
formed, but this was likely due to the P-O bonds of the

bisphosphonate overlapping with the P-O bonds of the hydroxyapatite formed. The FTIR spectra for all groups demonstrated the presence of carbonate substitution into the mineral,
as evidenced by peak at 873 cm−1, which represents C-O bond
bending, and the peak at 1,420 cm−1, which represents C-O
stretching (39–42, 44–46) (Fig. 5C). The peak at 873 cm−1 has
been suggested to be associated with type B carbonate, that is,
carbonate groups substituted for phosphate groups within hydroxyapatite (45). Finally, the peak seen at 1,650 to 1,655 cm−1
(Fig. 5C) has been associated with the amide I band of protein,
specifically C = O peptide double bond (41, 42, 44).
Atomic force microscopy based force spectroscopy (AFM-FS)
provided a comparison of the properties of our samples by
probing the forces experienced by the AFM tip when indenting
the sample (SI Appendix, Fig. S7). In this case, we measured the
tip-sample normalized detachment force (NDF), which represents the force needed by the AFM tip to snap free from the
sample. NDF was normalized by the detachment force from the
free solid substrate (mica) and used to characterize the mechanical properties and in turn composition and structure of the
samples. The NDF of the isolated EVs (SI Appendix, Fig. S7, red
bar) resulted significantly higher than that of the mineral (SI
Appendix, Fig. S7, green bar). This is intuitive and reasonable in
first approximation, given that a lower force is needed to detach
the tip from the hard mineral with respect to that needed to
detach it from the sticky lipid bilayer of the EVs. We found that
all five experimental groups (SI Appendix, Fig. S7, blue bars)
have a NDF which falls in between the values obtained for the
native EVs and the pure mineral. This characteristic intermediate physicochemical interaction with the AFM tip suggests that
the EV-nucleated microcalcifications are made of a “composite
material” of EVs and calcium phosphate mineral.
SEM and AFM imaging revealed that BiP treatment altered
microcalcification morphology in a time-dependent manner
(Fig. 6). While untreated microcalcifications were more denseappearing, elongated structures (Fig. 6A), BiP-treated microcalcifications varied in their morphology depending on the timing of BiP treatment. Microcalcifications from samples that
underwent early (day 2) BiP treatment had a significantly more
circular morphology compared to all other groups (Fig. 6 B and
I), with a ∼50% reduction in height measured by AFM (Fig. 6F).
In samples that underwent treatment on day 4, the resulting
microcalcifications had no significant difference in shape, size, or
height (Fig. 6 C, G, I, and J). Samples treated on day 2 or day 4

A

C

B

D

E

Fig. 3. The 3D collagen-EV platform mediated the deposition of calcium
phosphate mineral. (A) Collagen hydrogel following 8 d of incubation with
calcifying EVs, stained with a near-infrared fluorescent calcium tracer, and
imaged using confocal microscopy. (B) Representative EDS spectrum of a
microcalcification in the 3D collagen platform. (C) Microcalcification imaged
in the 3D collagen platform using SEM. EDS was conducted for this microcalcification, yielding elemental maps of phosphorous (D) and calcium (E).
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had a more fine-textured mineral structure compared to other
groups (Fig. 6 B and C). Following treatment on day 6, the final
microcalcifications observed were of a less circular, more elongated morphology akin to untreated controls (Fig. 6 A, D, and I).
While these microcalcifications were of a significantly larger area
compared to all other groups (Fig. 6J), their height measured by
AFM was reduced by ∼80% (Fig. 6H), and they visually
appeared to be composed of some areas of rough mineral aggregates and others of thin, sheet-like regions interrupted by
several gaps (Fig. 6D). Finally, FEA revealed a significant,
threefold reduction in the SCF predicted for microcalcifications
formed following single-dose BiP treatment at any time, versus
those from the control group (Fig. 7).
A mouse model of atherosclerosis was used to assess the effect
of BiP treatment on plaque-associated calcification in vivo.
ApoE−/− mice were fed an atherogenic diet and started on twice
weekly BiP treatment (ibandronate, 2 mg/kg per dose) (Fig. 8A)
at different stages of vascular calcification based on prior studies
of the time course of the onset of microcalcification formation
(18, 24, 47–49). Specifically, BiP was given after 5 wk of diet,
before the expected onset of microcalcification (“week 5 BiP”)
(48), after 10 wk of diet, at the expected time of initial microcalcification formation (“week 10 BiP”) (18, 24), or after 15 wk
of diet, once microcalcification formation has been established
(“week 15 BiP”) (18, 24, 47–49), further detailed in SI Appendix.
Density-dependent color SEM (DDC-SEM) (37) images were
obtained of atherosclerotic plaque-associated calcification in the
aortic root of these mice following 25 wk of diet (representative
histological images demonstrating atherosclerosis and calcification in these lesions are provided in SI Appendix, Figs. S8 and
S9). The images obtained from this mouse model visualized vascular calcification at a more advanced stage in which multiple
microcalcifications aggregate together into larger calcification
areas (Fig. 8), complementary to the images of individual microcalcifications visualized using our in vitro acellular platform
(Fig. 6).
In control mice, the areas of microcalcification (orange) were
more confluent with a larger average area per microcalcification
(Fig. 8 B and D), with a high degree of quantified surface
roughness (Fig. 8C). In the mice given BiP treatment prior to the
onset of calcification (week 5 of diet), the areas of microcalcification had a similar degree of quantified surface roughness
compared to the control group (Fig. 8C), but the average area
per microcalcification was smaller (Fig. 8 B and E). Compared to
the control and week 5 groups, the microcalcifications visualized
in the week 10 and week 15 groups were more loosely aggregated
together and of a significantly smaller average area (Fig. 8 B, F,
and G). In mice treated with BiP starting at the onset of calcification formation (week 10 of diet), the imaged mineral had the
lowest degree of surface roughness (Fig. 8 C and F). In comparison, mice started on BiP treatment once calcification formation had been established (week 15 of diet) had mineral that
was of a moderate degree of surface roughness (Fig. 8 C and G).
Thus, BiP treatment was associated with changes in the morphology of microcalcifications as they aggregated together in vivo,
just as we observed changes in individual microcalcification morphology following BiP treatment via the in vitro acellular platform
(Fig. 6 A–D, I, J vs. Fig. 8 B–G).
Discussion
This study was motivated by observed differences in cardiovascular outcomes among patients who started taking BiPs at different ages or different stages of cardiovascular disease (34–36).
Given that cardiovascular calcification, and especially the presence of microcalcifications, is a strong and independent risk
factor for adverse cardiac events, and BiPs are prescribed to treat
4 of 10 | PNAS
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pathologies of mineralization, we hypothesized that one role of
BiPs in modulating cardiovascular outcomes was by altering the
dynamics of EV-mediated microcalcification formation.
Using a 3D, acellular platform, our study unveiled a direct,
physicochemical interaction between the BiP ibandronate and
EV-nucleated microcalcifications. Our findings demonstrated that
early (day 0 and day 2) BiP treatment of calcifying EVs resulted in
smaller, more circular microcalcifications with a more finetextured mineral structure and no significant difference in the
total amount of mineral formed, compared to the control. In
contrast, samples that underwent later BiP treatment on day 6 of
incubation produced microcalcifications of a significantly larger
size with a rough and interrupted mineral structure, and a significantly greater amount of mineral measured overall compared to
all other groups, including the untreated control. These findings
were complemented by changes in calcific mineral morphology in
an in vivo mouse model of atherosclerosis, in which vascular calcification was captured at a more advanced stage of aggregation
within atherosclerotic lesions. While untreated mice and mice
started early (week 5 of diet) on BiP treatment demonstrated
plaque-associated calcification with a high degree of surface
roughness, later treatment (weeks 10 and 15 of diet) resulted in
mineral with a lower degree of roughness, and all BiP-treated
groups (weeks 5, 10, and 15 of diet) had a smaller average area
per individual microcalcification as compared to the control.

A
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Fig. 4. BiP reduced the maximum size of calcific EV aggregates visualized
via SEM. Changes in microcalcification size can be seen at low magnification
(A vs. B) and high magnification (C vs. D). The average cross-sectional area of
the five largest microcalcifications per high-powered field was significantly
lower in the BiP-treated group versus the control group (E, n = 3 biological
replicates). Elemental calcium and phosphorous composition of control and
BiP-treated microcalcifications measured via EDS (F, nine technical replicates
per group, n = 1 biological replicates, ***P < 0.001, ****P < 0.0001, error bars
represent SD).
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EV-driven mineral formation in vitro begins after 3 d of incubation in osteogenic medium (24). Thus, treatment with BiP
within the first 3 d of incubation leads to microcalcification formation in the presence of BiP molecules, whereas treatment at
later time points introduces the influence of BiP to microcalcifications that have already started to form. BiPs are analogous
to pyrophosphate, a natural inhibitor of mineral formation that acts
to block calcium and phosphate ions from forming crystals, inhibit
crystal aggregation, and limit mineral transformation from amorphous calcium phosphate to hydroxyapatite (29). Our findings
demonstrated that early BiP treatment resulted in the formation of
smaller, circular, less crystalline but more numerous microcalcifications, which may be attributable to the pyrophosphate-like
activity of BiP limiting more expansive aggregation and mineralization of calcifying EVs. BiP adsorption onto mineral crystals may
further alter crystal growth, size, aggregation, and integrity (50, 51),
leading to the observed changes. We further expected a reduction
in mineral formation under the influence of BiP, but the overall
amount of mineral was unchanged following early BiP treatment.
This implies that the main effect of BiP on EV-mediated mineralization is not an antimineralization effect, but rather that BiP
influence the morphology and maturity of mineral formed. In addition, it is possible that the concentration of BiP was too low to
inhibit mineral formation entirely, and future studies should further explore the effect of different BiP concentrations on EVmediated microcalcification formation.
In contrast, treatment with BiP on day 6 of incubation resulted
in microcalcifications that were larger but thinner, with interruptions to their internal structure. Further, in the acellular
system there was a greater total amount of mineral formed in
this day 6 group, though the mineral was less crystalline compared to untreated samples. If the effect of later treatment with
BiP solely mimicked pyrophosphate, overall we would expect to
observe microcalcifications of smaller or equal size to those
formed in the absence of BiP, and a reduced or equal amount of
mineral measured on day 8. BiP molecules adsorb onto the hydrated surface layer of calcium phosphate mineral (51). In our
system, this interaction may have resulted in an alteration of
surface chemistry, and this combined with the greater surface
area of microcalcifications formed may have led to an increase in
mineral detected by the binding assay. However, the mechanism
by which the later addition of BiP to already forming microcalcifications led to the formation of larger, thinner, interrupted
microcalcifications is unknown and merits further investigation.

Our in vivo findings captured the effect of BiP on vascular
calcification at a later stage of the mineralization process, in
which individual microcalcifications aggregate together to form
larger calcification areas. Initiating BiP treatment at any time,
either before (week 5 of diet), at the onset (week 10 of diet), or
after the onset (week 15 of diet) of microcalcification formation, decreased the degree to which nascent microcalcifications
aggregated together into larger microcalcifications, as quantified by the reduction in the area of the microcalcifications
analyzed. Further, later BiP treatment decreased the surface
roughness of the mineral that formed. Our in vivo findings
complemented our in vitro findings, namely, that BiP changed the
morphology of mineral formed. These in vivo changes to larger
mineral structures may be attributable to the pyrophosphate-like
activity of BiP as it adsorbs onto calcifying EVs and microcalcifications as they form and grow, altering not only the morphology of individual microcalcifications, but also the manner
by which microcalcifications aggregate together to form larger
calcified structures.
Through imaging analyses, assessment of chemical composition, and FEA, we confirmed that microcalcifications formed in
our 3D platform recapitulated human atheroma-associated
microcalcifications in morphology and composition and were
predicted to cause a notable increase in fibrous cap tensile stress.
Only a subset of plaque-associated microcalcifications have highrisk features associated with plaque rupture (9), which are related to size, morphology, alignment within the fibrous cap, and
spatial relation to other microcalcifications (9, 10, 52). Therefore, the ability to recapitulate plaque-destabilizing microcalcifications is of particular clinical interest.
This study demonstrated that treatment with BiP at any time
point significantly decreased the predicted fibrous cap tensile stress
attributable to microcalcifications formed using the 3D platform,
despite variation in microcalcification size and morphology among
these BiP-treated groups. Importantly, our findings further suggest
that BiP treatment mediated changes in mineral morphology
in vivo, in a time-dependent manner. Additional in vivo studies are
needed to assess the biomechanical and physiologic consequences
of these in vivo morphologic changes as they relate to the risk of
plaque rupture and adverse cardiac outcomes.
Analysis of the FTIR spectra of untreated and BiP-treated
samples revealed that in all conditions, the mineral formed was
carbonated hydroxyapatite. Spectral analysis of BiP-treated samples
suggested that the mineral formed was likely less mature and less
crystalline than untreated controls. Future studies should further

Ruiz et al.
Nanoanalytical analysis of bisphosphonate-driven alterations of microcalcifications using a
3D hydrogel system and in vivo mouse model

PNAS | 5 of 10
https://doi.org/10.1073/pnas.1811725118

CELL BIOLOGY

Fig. 5. The formation of microcalcifications varied significantly with single-dose BiP treatment in a time-dependent manner. Schematic depicting the experimental setup for treating samples with a single dose of BiP at different times (A). The amount of calcium phosphate mineral formed in each sample was
measured using a fluorescent-based assay and varied significantly across treatment groups (B, P = 0.0025 via one-way ANOVA; n = 5 biological replicates),
with a significant difference between control and day 6 groups (*P = 0.027, error bars represent SD). The chemical composition of microcalcifications formed
in each sample was measured using FTIR, with a representative spectrum shown for each group (C).
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Fig. 6. BiP treatment altered microcalcification morphology in a time-dependent manner. SEM (A–D) and AFM (E–H) were used to image microcalcifications
formed in 3D collagen hydrogels that were treated at different times with a single dose of BiP. Microcalcification circularity (I) and size (J) significantly varied
across time points (n = 4 biological replicates for control, day 2, day 4 groups, n = 2 biological replicates for day 6 group; *P < 0.05, **P < 0.01, ***P < 0.001,
error bars represent SD).

investigate the composition and crystallinity of EV-derived mineral
with and without BiP treatment, both using more advanced FTIR
spectral analysis techniques, as well as complementary methods
such as Raman spectroscopy and direct measures of crystallinity.
Additionally, the FTIR analysis did not reveal any direct evidence of BiP incorporation into the mineral formed, but this
was likely secondary to the P-O bonds of the bisphosphonate
blending in with the P-O bonds of the hydroxyapatite formed.
Future studies using bisphosphonates with more distinct
chemical structures should be used to allow for the detection of
bisphosphonates using FTIR.
We did not observe any collagen fibril mineralization or other
collagen changes in any of our treatment conditions. However, we
did visualize that EVs had an affinity for collagen fibrils and used
these fibrils as scaffolding as the EVs aggregate and mineralize.
We recently showed that calcifying EVs contain annexin A1,
which functioned as a membrane-binding protein that mediated
EV aggregation (28). Other annexins were also implicated in
interactions with collagen in the extracellular matrix and have
been hypothesized to mediate calcium influx into EVs (11, 26,
28, 53). Future studies should leverage our 3D platform to
study EV-collagen interactions and how BiP may modify said
interactions.
6 of 10 | PNAS
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Future investigations are also needed to examine the impact of
BiP on the cells that produce EVs (e.g., vSMCs and macrophages),
and if the calcification potential of EVs is altered by exposure of
the parent cells to BiP, particularly in light of the known osteoclastmediated effects of BiP on bone turnover (31). Additionally, our
findings were limited to the consequences of ibandronate treatment, and additional explorations are needed to characterize the
effects of different BiPs on microcalcification formation, noting
which effects are shared and which are BiP specific.
Furthermore, it remains to be determined if paradoxical cardiovascular outcomes following BiP treatment are, at least in
part, a downstream consequence of the impact of BiP treatment
on bone metabolism. Additional studies are required to tease
apart the relative contributions of physicochemical mechanisms
and cellular mechanisms at the level of vascular tissue versus altered circulating factors downstream of bone metabolism, as they
relate to vascular calcification. While future studies are needed to
examine the impact of BiP on vascular microcalcification formation and adverse cardiac outcomes in vivo in both animal and
human studies, our findings provide evidence that differences
observed in vivo could be the result, at least in part, from an effect
of BiP on EV mineralization directly, a process that cannot be
isolated in a more complex, in vivo system.
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Fig. 7. BiP treatment altered the predicted fibrous cap tensile stress attributed to single microcalcifications, in a time-dependent manner. A–D
demonstrate FEA analysis of representative microcalcifications treated with
BiP at different time points. E quantifies the average stress concentration
factor for five representative microcalcifications from each BiP-treated
group, as compared to untreated microcalcifications (control), (n = 3 biological replicates per group, except day 6 group, which reflects n = 2 biological replicates, error bars represent SD, ***P < 0.0001).

Calcification plays a key role in determining the stability of an
atherosclerotic plaque. Pathologic calcification is an active but
disordered process that produces one or more types of immature,
poorly crystalline minerals that have proven difficult to characterize (54, 55). More in-depth studies are required to obtain a
precise understanding of the material properties and chemical
characteristics unique to vascular calcific deposits, how BiP treatment alters the properties and morphology of microcalcifications,
and how these changes influence the risk of plaque rupture. Our 3D
collagen platform, amenable to high-resolution, multimodal analyses, has the potential to advance our understanding of the conditions and processes that drive the formation of plaque-destabilizing
microcalcifications, as well as screen anticalcification drugs that aim
to mitigate cardiovascular risk.
Materials and Methods
Cell Culture and Isolation of Extracellular Vesicles. Human coronary artery
SMCs (PromoCell) were cultured for 14 d in either control “normal” medium
of Dulbecco’s Modified Eagle Medium (DMEM) plus 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin, or calcifying “osteogenic” medium
composed of control medium plus 10 nM dexamethasone, 100 μM L-ascorbic
acid, and 10 mM β-glycerophosphate. The media were then exchanged for
control or calcifying medium containing only 0.1% FBS, and after 24 h the

conditioned media was centrifuged and EV-containing supernatants were
isolated. EV size distribution was quantified using nanoparticle tracking
analysis (NTA), and calcification potential was assessed by measuring the
activity of tissue non-specific alkaline phosphatase within the EV suspension,
as detailed in SI Appendix.
EV-Nucleated Calcification in Collagen Hydrogels or in Suspension. Calcifying
EVs were washed and concentrated using centrifugal filtration. The final
vesicle suspension volume was adjusted to achieve a vesicle concentration
four times that of the original vesicle concentration in conditioned media.
The 3D collagen platform consisted of collagen hydrogels (5% type I collagen
in 0.1% FBS calcifying medium) cast onto amino-silanated glass coverslips, as
detailed in SI Appendix.
EVs were incubated for 8 d at 37 °C either with coverslip-adhered
collagen hydrogels or in suspension. At the assigned time points,
0.4 mM ibandronate in water (Sigma-Aldrich) or an equivalent volume of
water (untreated control) was added to the appropriate samples (final
ibandronate concentration 0.05 mM). EV mineralization in suspension
was quantified using a fluorescent-based mineral-binding dye (Lonza,
OsteoImage), with results for Fig. 5B normalized using the average of the
“no treatment” group for each biological replicate (n = 5 biological
replicates).
Analysis of Calcifications Formed in 3D Collagen Platform. For SEM and EDS
analysis, the coverslip-adhered hydrogels were fixed, dehydrated in grades
of ethanol, subjected to critical point drying, mounted onto aluminum stubs,
sputter coated with 5 nm of 80:20 platinum:palladium, and uncoated edges
covered with silver adhesive. Samples were imaged in a Supra55VP FESEM
(Zeiss) using a secondary electron in-lens detector and an EDS detector for
elemental analysis. These protocols are further described in SI Appendix. An
algorithm was custom-written (MATLAB) to calculate the average area of
the five largest microcalcifications per high-powered field (2k magnification)
imaged using SEM. Characteristics of individual microcalcifications (circularity and area) were measured using ImageJ. The MATLAB and ImageJ
analyses are further detailed in SI Appendix.
For TEM, collagen hydrogels were prepared as above but cast in chambered coverglass wells. Calcifying EVs were concentrated 7.5× using centrifugal filtration (as above) and added to each gel. Following 8 d of
incubation, samples were fixed and postfixed, dehydrated in grades of alcohol, infiltrated overnight in a 1:1 mixture of propyleneoxide and TAAB
Epon, embedded in TAAB Epon, and polymerized. Ultrathin sections (∼80
nm) were picked up onto copper grids stained with lead citrate and examined in a JEOL 1200EX transmission electron microscope. These protocols are
further described in SI Appendix.
FTIR. For FTIR, vesicles were prepared and incubated in suspension as above,
but the concentration of EVs used was 1× rather than 4×. Samples then
underwent ultracentrifugation, and the pellet was dropcast onto an untreated glass slide. A motorized stage and polarized optical microscope were
used to identify regions for analysis. Attenuated total reflectance mode
(single bounce Ge crystal) was used to collect spectral data in a range from
4,000 to 600 cm−1. Each spectrum was normalized to the sum of the values
from 2,000 to 700 cm−1. These protocols are further detailed in SI Appendix.
Confocal Microscopy. Confocal microscopy was used as a complementary
imaging technique to visualize calcific deposits in the 3D hydrogels. Samples
were stained using a near-infrared calcium tracer (OsteoSense 680, PerkinElmer), mounted on slides, and imaged by obtaining z-stack optical sections,
each stack encompassing the entire fluorescent signal present within that
region of the gel. The confocal microscopy protocol is further described in
SI Appendix.
Multiscale FEA. A global finite element (FE) model and three fibrous cap
submodels were prepared to obtain the SCF produced by the presence of a
single microcalcification. For the global model, a 3D FE volumetric tetrahedral
mesh was created, depicting the soft tissue, lipid, and cap of the atheroma. A
total of 120 mmHg was applied as hydrostatic load on the lumen of the artery,
and stresses and strains were recorded at each node. The 3D maps of stresses
and strains were obtained for each SEM-imaged microcalcification. Control
tests were performed by assigning soft tissue, hyperelastic properties to the
3D volume occupied by the microcalcifications. Stress concentration was
calculated as the ratio of the stresses with and without microcalcifications
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Fig. 8. BiP treatment altered atherosclerotic plaque-associated calcification morphology in a time-dependent manner. ApoE−/− mice were fed an atherogenic diet and started on twice weekly BiP (ibandronate) treatment at various stages of atherosclerotic plaque development and calcification (A). Histological
sections of aortic tissue were imaged using DDC-SEM. Quantitative image analysis was performed to measure the average area per individual calcification in
each image (B) and the average surface roughness of calcific mineral in each image (C, n = 3 biological replicates per group; *P < 0.05, **P < 0.01, error bars
represent SE of mean). Representative DDC-SEM images from each treatment group are shown (D–G).

and measured for five distinct microcalcifications per treatment group representing three biological replicates per group. A full description of the FEA
process can be found in SI Appendix.
AFM. EVs were concentrated 4× and incubated in suspension and treated
with ibandronate as above. Following 8 d of incubation, samples underwent
ultracentrifugation, and the pellets were resuspended in MilliQ water with
protease inhibitor 1:1,000, and spotted onto freshly cleaved mica sheets.
Representative images were acquired with a NaioAFM (Nanosurf AG)
equipped with Multi75Al-G probe in tapping mode. Imaging analysis was
performed with the software WSxM 5.0 image (56). For detachment force
measurements, samples were imaged using a NaioAFM (Nanosurf AG)
equipped with ContAl-G probe (nominal spring constant k ∼ 0.2 N·m−1) in
contact mode. The AFM probe was then positioned above the center of each
EV/microcalcification, and individual force curves were recorded with a
Z-starting offset of 500 nm and a Z-piezo speed of XYZ 10 μm·s−1. Multiple
EV/microcalcifications structures were probed in order to obtain a NDF
value, representative of each sample. The software SPIP 6.7.2 (Image Metrology A/S) was then used to analyze the force-distance curves and obtain
the detachment force values. These protocols are further described in
SI Appendix.
Human Carotid Endarterectomy Tissue. Human carotid artery samples were
obtained from patients undergoing endarterectomy, further describted in SI
Appendix. The image shown was generated using DDC-SEM, as detailed below.
Animal Study: Atherogenic Mouse Model Receiving Bisphosphonate Treatment.
Eight-week-old mice homozygous for the Apoetm1Unc mutation (B6.129P2Apoetm1Unc/J, ApoE−/−) were purchased from The Jackson Laboratory, with
a mortality rate for this experiment of <9% as expected in the setting of
some challenges with animal handling unrelated to the experimental design. After 2 wk of incubation and feeding with chow diet, n = 16 animals
(10 wk old) received an atherogenic diet (ENVIGO, TD.88137 adjusted calories diet, 42% from fat) for 25 wk. The animals were sorted into four groups,
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n = 4 animals per group. There was no significant difference among endpoint animal body weight among the mice in each group (SI Appendix, Fig.
S10). Three groups received twice weekly subcutaneous injections of
bisphosphonate ibandronate sodium (2 mg/kg mouse per dose, APEXBIO)
after 5, 10, and 15 wk of diet, respectively, further detailed in SI Appendix.
After 25 wk, the mice were killed, and the aortas were resected, fixed, and
embedded, cut into 18-μm thick histological sections (further detailed in SI
Appendix), and prepared for SEM, detailed below. Histology was also performed including H&E and Alizarin Red S staining, as detailed in
SI Appendix.
Density-Dependent Color SEM. Histological sectioned samples were secured to
an aluminum sample holder with carbon tape, and silver paint was applied to
the area immediately surrounding each sample, which was then coated with
carbon. Following the coating procedure, samples were imaged by an SEM
(Carl Zeiss EVO 25 SEM) operated at 15 kV (mouse tissue samples) or 10 kV
(human tissue sample). The secondary electron (SE) and backscattered
electron (BSE) detectors were used to image the same region of the samples.
To obtain DDC-SEM (37), using ImageJ software, both images were stacked
and the SE image was assigned to the green channel, whereas the BSE image
was assigned to the red channel.
Quantitative Analysis of In Vivo Calcification Size and Roughness. To assess the
average of the mineral surface roughness (Ra) and the average area of
microcalcifications imaged from histologic samples via DDC-SEM, a custom
image analysis script was developed in MATLAB, based on previous
methods of quantifying roughness by analyzing deviations in grayscale
intensity (57–59), further described in SI Appendix. The Ra and area values
were averaged across images for each mouse, and the data reported represent the mean values calculated from different mice, n = 3 biological
replicates.
Statistical Analyses. Error bars represent SD unless stated otherwise. Quantitative data were analyzed for statistical significance using a Student’s t test
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